Enhanced antitumor effects of suicide gene therapy by simultaneous transfer of GM-CSF gene in leukemia-bearing mice

1998 ◽  
Vol 10 (2) ◽  
pp. 79-83
Author(s):  
Dianwen Ju ◽  
Xuetao Cao ◽  
Yizhi Yu ◽  
Qun Tao ◽  
Baomei Wang ◽  
...  

2008 ◽  
Vol 16 (10) ◽  
pp. 1719-1726 ◽  
Author(s):  
Takayuki Suzuki ◽  
Fuminori Sakurai ◽  
Shin-ichiro Nakamura ◽  
Emi Kouyama ◽  
Kenji Kawabata ◽  
...  


2016 ◽  
Vol 13 (4) ◽  
pp. 3213-3219 ◽  
Author(s):  
LUN WU ◽  
WEN-BO ZHOU ◽  
FENG SHEN ◽  
WEI LIU ◽  
HONG-WEI WU ◽  
...  






2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e14610-e14610
Author(s):  
H. Akbulut ◽  
A. Coleri ◽  
N. Acikgoz ◽  
G. Sahin ◽  
P. Ozkal ◽  
...  

e14610 Background: Suicide gene therapy is one of the promising treatment modalities in cancer treatment. Combination of an immunotherapy modality with suicide gene therapy would increase the tumor eradciating efficacy of either treatment strategy used alone. Methods: In the current study, we constructed adenoviral vectors carying ytosine deaminase (CD), granulocyte macrophage-colony stimulating factor (GM-CSF) vectors. We tested the in vitro efficacy of the vectors in both human and mouse tumor cell lines and in a syngeneic mouse model of colon cancer with tumor explants of CRL 2638 cells. Results: Our results show that the vectors carrying CD/GM-CSF transcription units are effective in terms of killing of tumor cells when 5-FC added. Addition of GM-CSF transgene induced a significant amount of GM-CSF secretion (250 pg/ml/105 cells) of infected cells. In the syngeneic colon cancer model, addition of GM-CSF significantly increased tumor-specific cellular immune response when compared to suicide gene therapy alone. (p<0.01). Likewise, GM-CSF addition caused a 8 times reduction in the ratio of Tregs infiltrating the tumor nodules (p<0.001). Accordingly, GM-CSF decreased the tumor growth by 2 times an d increased the median survival time by 50% (p<0.01). Conclusions: These impressive results of in-vitro cytotoxicity and encouraging results of in-vivo testing of the our newly constructed GM-CSF carrying vector suggest a potential for the use of the vector for the treament of established tumors by inducing tumor specific immune response. No significant financial relationships to disclose.



Gene Therapy ◽  
2000 ◽  
Vol 7 (19) ◽  
pp. 1672-1679 ◽  
Author(s):  
D W Ju ◽  
Y Yang ◽  
Q Tao ◽  
W G Song ◽  
L He ◽  
...  




2001 ◽  
Vol 120 (5) ◽  
pp. A10-A10
Author(s):  
M YAMAMOTO ◽  
R ALEMANY ◽  
Y ADACHI ◽  
W GRIZZLE ◽  
D CURIEL


2020 ◽  
Vol 3 (8) ◽  
pp. 2000007
Author(s):  
Lucia Salvioni ◽  
Stefania Zuppone ◽  
Francesco Andreata ◽  
Matteo Monieri ◽  
Serena Mazzucchelli ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document